Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September
Foghorn Therapeutics (Nasdaq: FHTX), a clinical-stage biotech company, announced its participation in two upcoming investor conferences in September 2024. The company will attend the Wells Fargo Healthcare Conference on September 4 for one-on-one meetings. At the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, Foghorn's President and CEO, Adrian Gottschalk, will give a presentation at 8:30 a.m. EDT and participate in one-on-one meetings.
Foghorn is pioneering a new class of medicines that correct abnormal gene expression to treat serious diseases, with an initial focus on oncology. Their Gene Traffic Control® platform and broad pipeline aim to transform lives across various diseases. A webcast of the Morgan Stanley presentation will be available on the company's website for 30 days.
Foghorn Therapeutics (Nasdaq: FHTX), un'azienda biotech in fase clinica, ha annunciato la sua partecipazione a due prossime conferenze per investitori a settembre 2024. L'azienda parteciperà al Wells Fargo Healthcare Conference il 4 settembre per incontri individuali. Il Morgan Stanley 22nd Annual Global Healthcare Conference si terrà il 6 settembre, durante il quale il Presidente e CEO di Foghorn, Adrian Gottschalk, effettuerà una presentazione alle 8:30 a.m. EDT e parteciperà a incontri individuali.
Foghorn sta innovando una nuova classe di farmaci che correggono l'espressione genica anomala per trattare malattie gravi, con un focus iniziale sull'oncologia. La loro piattaforma Gene Traffic Control® e il suo ampio portafoglio intendono trasformare le vite attraverso varie malattie. Una registrazione della presentazione di Morgan Stanley sarà disponibile sul sito web dell'azienda per 30 giorni.
Foghorn Therapeutics (Nasdaq: FHTX), una empresa biotech en etapa clínica, anunció su participación en dos próximas conferencias para inversores en septiembre de 2024. La empresa asistirá a la Wells Fargo Healthcare Conference el 4 de septiembre para reuniones uno a uno. En la Morgan Stanley 22nd Annual Global Healthcare Conference el 6 de septiembre, el Presidente y CEO de Foghorn, Adrian Gottschalk, dará una presentación a las 8:30 a.m. EDT y participará en reuniones individuales.
Foghorn está pionera en una nueva clase de medicamentos que corrigen la expresión génica anormal para tratar enfermedades graves, con un enfoque inicial en oncología. Su plataforma Gene Traffic Control® y su amplia cartera tienen como objetivo transformar vidas a través de diversas enfermedades. Una transmisión de la presentación de Morgan Stanley estará disponible en el sitio web de la empresa durante 30 días.
Foghorn Therapeutics (Nasdaq: FHTX)는 임상 단계의 생명공학 회사로, 2024년 9월에 열리는 두 개의 투자자 콘퍼런스에 참여할 것이라고 발표했습니다. 이 회사는 9월 4일 Wells Fargo Healthcare Conference에 참석하여 개별 미팅을 가질 예정입니다. 9월 6일 Morgan Stanley 22nd Annual Global Healthcare Conference에서 Foghorn의 사장 겸 CEO인 Adrian Gottschalk는 오전 8시 30분 EDT에 발표를 하고, 개별 미팅에 참여할 것입니다.
Foghorn은 비정상적인 유전자 발현을 교정하여 중대한 질병을 치료하기 위한 새로운 약물 클래스의 개척에 나서고 있으며, 초기에는 종양학에 중점을 두고 있습니다. 그들의 Gene Traffic Control® 플랫폼과 폭넓은 파이프라인은 여러 질병에 걸쳐 삶을 변화시키는 것을 목표로 하고 있습니다. Morgan Stanley 발표의 웹캐스트는 회사 웹사이트에서 30일 동안 제공될 것입니다.
Foghorn Therapeutics (Nasdaq: FHTX), une entreprise biopharmaceutique en phase clinique, a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre 2024. L'entreprise assistera à la Wells Fargo Healthcare Conference le 4 septembre pour des réunions individuelles. Lors de la Morgan Stanley 22nd Annual Global Healthcare Conference le 6 septembre, le Président et CEO de Foghorn, Adrian Gottschalk, fera une présentation à 8h30 EDT et participera à des réunions individuelles.
Foghorn est pionnière dans une nouvelle classe de médicaments qui corrigent l'expression génique anormale pour traiter des maladies graves, avec un accent initial sur l'oncologie. Leur plateforme Gene Traffic Control® et leur large pipeline visent à transformer des vies à travers diverses maladies. Un webinaire de la présentation de Morgan Stanley sera disponible sur le site web de l'entreprise pendant 30 jours.
Foghorn Therapeutics (Nasdaq: FHTX), ein biopharmazeutisches Unternehmen in klinischer Phase, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 angekündigt. Das Unternehmen wird am 4. September an der Wells Fargo Healthcare Conference für Einzelgespräche teilnehmen. Am 6. September wird Foghorn's Präsident und CEO, Adrian Gottschalk, um 8:30 Uhr EDT eine Präsentation auf der Morgan Stanley 22nd Annual Global Healthcare Conference halten und an Einzelgesprächen teilnehmen.
Foghorn entwickelt eine neue Medikamentenklasse, die abnormale Genexpression korrigiert, um schwerwiegende Krankheiten zu behandeln, wobei zunächst der Schwerpunkt auf Onkologie liegt. Ihre Plattform Gene Traffic Control® und die breite Pipeline zielen darauf ab, das Leben bei verschiedenen Krankheiten zu verwandeln. Ein Webcast der Morgan Stanley Präsentation wird für 30 Tage auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the 2024 Wells Fargo Healthcare Conference and presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.
2024 Wells Fargo Healthcare Conference
- Management will participate in one-on-one meetings on Wednesday, September 4
Morgan Stanley 22nd Annual Global Healthcare Conference
- Presentation: Friday, September 6, 2024, at 8:30 a.m. EDT at the Marriott Marquis, New York, New York
- Foghorn Presenter: Adrian Gottschalk, President and Chief Executive Officer
- Please find a link to the webcast here
- Management will also participate in one-on-one meetings on Friday, September 6
A webcast of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website, www.foghorntx.com, and will be available for 30 days.
About Foghorn Therapeutics
Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information about the Company, and follow us on X and LinkedIn.
Contact:
Karin Hellsvik, Foghorn Therapeutics Inc. (Investors & Media)
khellsvik@foghorntx.com
FAQ
When is Foghorn Therapeutics (FHTX) participating in the Wells Fargo Healthcare Conference?
What is the date and time of Foghorn Therapeutics' (FHTX) presentation at the Morgan Stanley Global Healthcare Conference?
Who will be presenting for Foghorn Therapeutics (FHTX) at the Morgan Stanley conference?
Where can investors access the webcast of Foghorn Therapeutics' (FHTX) Morgan Stanley conference presentation?
What is the main focus of Foghorn Therapeutics' (FHTX) Gene Traffic Control® platform?
